Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.26 +0.01 (+0.07%)
Streaming Delayed Price Updated: 11:42 AM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. ↗
 
Via Benzinga
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
News headline image
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.